Institut national d’excellence en santé et services sociaux (INESSS), whose missions is “to promote clinical excellence and the efficient use of resources in the health and social services sector” is recommending ORLADEYO® (berotralstat), an oral treatment, be reimbursed for the prevention of HAE attacks in adults and pediatric patients 12 years of age and older in Quebec. Private and public drug plans in Quebec use INESSS’s recommendation to help decide what to include in their formularies, bringing HAE patients in Quebec one step closer to accessing this oral treatment.
HAE Canada proudly provided a patient submission to INESSS to help the organzation make an informed decision. Thank you to the HAE Canada Advocacy Committee and HAE International’s Tony Castaldo (CEO) and Henrik Balle-Boysen (VP and COO) for contributing to this patient submission.
Please click the links below for BioCryst Pharmaceuticals’ press releases.